Selected research
Industry Research
Mucin 1 Industry Research Report 2026
Market perspective
The global Mucin 1 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mucin 1 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mucin 1 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mucin 1 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mucin 1 include Merck KGaA, Vaxil Bio Therapeutics Ltd, Transgene SA, Minerva Biotechnologies Corp, GeoVax Labs Inc, Etubics Corp, Boehringer Ingelheim GmbH, Bavarian Nordic A/S and Akshaya Bio Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mucin 1 market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mucin 1 Market by Company
Merck KGaA
Vaxil Bio Therapeutics Ltd
Transgene SA
Minerva Biotechnologies Corp
GeoVax Labs Inc
Etubics Corp
Boehringer Ingelheim GmbH
Bavarian Nordic A/S
Akshaya Bio Inc
Mucin 1 Segment by Type
TG-4010
BI-1361849
GO-2032c
ImMucin
Others
Mucin 1 Segment by Application
Colon Cancer
Ovarian Cancer
Prostate Cancer
Breast Cancer
Others
Mucin 1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mucin 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mucin 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mucin 1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mucin 1 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mucin 1 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mucin 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- TG-4010
- BI-1361849
- GO-2032c
- ImMucin
- Others
Applications
- Colon Cancer
- Ovarian Cancer
- Prostate Cancer
- Breast Cancer
- Others
Companies covered
- Merck KGaA
- Vaxil Bio Therapeutics Ltd
- Transgene SA
- Minerva Biotechnologies Corp
- GeoVax Labs Inc
- Etubics Corp
- Boehringer Ingelheim GmbH
- Bavarian Nordic A/S
- Akshaya Bio Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mucin 1 Market Size (2021-2032)
- 2.2.2 Global Mucin 1 Sales (2021-2032)
- 2.2.3 Global Mucin 1 Market Average Price (2021-2032)
- 2.3 Mucin 1 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 TG-4010
- 2.3.3 BI-1361849
- 2.3.4 GO-2032c
- 2.3.5 ImMucin
- 2.3.6 Others
- 2.4 Mucin 1 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Colon Cancer
- 2.4.3 Ovarian Cancer
- 2.4.4 Prostate Cancer
- 2.4.5 Breast Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mucin 1 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mucin 1 Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Mucin 1 Revenue of Manufacturers (2021-2026)
- 3.4 Global Mucin 1 Average Price by Manufacturers (2021-2026)
- 3.5 Global Mucin 1 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mucin 1, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mucin 1, Product Type & Application
- 3.8 Global Manufacturers of Mucin 1, Established Date
- 3.9 Global Mucin 1 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck KGaA
- 4.1.1 Merck KGaA Company Information
- 4.1.2 Merck KGaA Business Overview
- 4.1.3 Merck KGaA Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck KGaA Mucin 1 Product Portfolio
- 4.1.5 Merck KGaA Recent Developments
- 4.2 Vaxil Bio Therapeutics Ltd
- 4.2.1 Vaxil Bio Therapeutics Ltd Company Information
- 4.2.2 Vaxil Bio Therapeutics Ltd Business Overview
- 4.2.3 Vaxil Bio Therapeutics Ltd Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Vaxil Bio Therapeutics Ltd Mucin 1 Product Portfolio
- 4.2.5 Vaxil Bio Therapeutics Ltd Recent Developments
- 4.3 Transgene SA
- 4.3.1 Transgene SA Company Information
- 4.3.2 Transgene SA Business Overview
- 4.3.3 Transgene SA Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Transgene SA Mucin 1 Product Portfolio
- 4.3.5 Transgene SA Recent Developments
- 4.4 Minerva Biotechnologies Corp
- 4.4.1 Minerva Biotechnologies Corp Company Information
- 4.4.2 Minerva Biotechnologies Corp Business Overview
- 4.4.3 Minerva Biotechnologies Corp Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Minerva Biotechnologies Corp Mucin 1 Product Portfolio
- 4.4.5 Minerva Biotechnologies Corp Recent Developments
- 4.5 GeoVax Labs Inc
- 4.5.1 GeoVax Labs Inc Company Information
- 4.5.2 GeoVax Labs Inc Business Overview
- 4.5.3 GeoVax Labs Inc Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GeoVax Labs Inc Mucin 1 Product Portfolio
- 4.5.5 GeoVax Labs Inc Recent Developments
- 4.6 Etubics Corp
- 4.6.1 Etubics Corp Company Information
- 4.6.2 Etubics Corp Business Overview
- 4.6.3 Etubics Corp Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Etubics Corp Mucin 1 Product Portfolio
- 4.6.5 Etubics Corp Recent Developments
- 4.7 Boehringer Ingelheim GmbH
- 4.7.1 Boehringer Ingelheim GmbH Company Information
- 4.7.2 Boehringer Ingelheim GmbH Business Overview
- 4.7.3 Boehringer Ingelheim GmbH Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Boehringer Ingelheim GmbH Mucin 1 Product Portfolio
- 4.7.5 Boehringer Ingelheim GmbH Recent Developments
- 4.8 Bavarian Nordic A/S
- 4.8.1 Bavarian Nordic A/S Company Information
- 4.8.2 Bavarian Nordic A/S Business Overview
- 4.8.3 Bavarian Nordic A/S Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bavarian Nordic A/S Mucin 1 Product Portfolio
- 4.8.5 Bavarian Nordic A/S Recent Developments
- 4.9 Akshaya Bio Inc
- 4.9.1 Akshaya Bio Inc Company Information
- 4.9.2 Akshaya Bio Inc Business Overview
- 4.9.3 Akshaya Bio Inc Mucin 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Akshaya Bio Inc Mucin 1 Product Portfolio
- 4.9.5 Akshaya Bio Inc Recent Developments
5 Global Mucin 1 Market Scenario by Region
- 5.1 Global Mucin 1 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mucin 1 Sales by Region: 2021-2032
- 5.2.1 Global Mucin 1 Sales by Region: 2021-2026
- 5.2.2 Global Mucin 1 Sales by Region: 2027-2032
- 5.3 Global Mucin 1 Revenue by Region: 2021-2032
- 5.3.1 Global Mucin 1 Revenue by Region: 2021-2026
- 5.3.2 Global Mucin 1 Revenue by Region: 2027-2032
- 5.4 North America Mucin 1 Market Facts & Figures by Country
- 5.4.1 North America Mucin 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mucin 1 Sales by Country (2021-2032)
- 5.4.3 North America Mucin 1 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mucin 1 Market Facts & Figures by Country
- 5.5.1 Europe Mucin 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mucin 1 Sales by Country (2021-2032)
- 5.5.3 Europe Mucin 1 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mucin 1 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mucin 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mucin 1 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mucin 1 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mucin 1 Market Facts & Figures by Country
- 5.7.1 South America Mucin 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mucin 1 Sales by Country (2021-2032)
- 5.7.3 South America Mucin 1 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Mucin 1 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mucin 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mucin 1 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mucin 1 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Mucin 1 Sales by Type (2021-2032)
- 6.1.1 Global Mucin 1 Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Mucin 1 Sales Market Share by Type (2021-2032)
- 6.2 Global Mucin 1 Revenue by Type (2021-2032)
- 6.2.1 Global Mucin 1 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mucin 1 Revenue Market Share by Type (2021-2032)
- 6.3 Global Mucin 1 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mucin 1 Sales by Application (2021-2032)
- 7.1.1 Global Mucin 1 Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Mucin 1 Sales Market Share by Application (2021-2032)
- 7.2 Global Mucin 1 Revenue by Application (2021-2032)
- 7.2.1 Global Mucin 1 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mucin 1 Revenue Market Share by Application (2021-2032)
- 7.3 Global Mucin 1 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mucin 1 Value Chain Analysis
- 8.1.1 Mucin 1 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mucin 1 Production Mode & Process
- 8.2 Mucin 1 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mucin 1 Distributors
- 8.2.3 Mucin 1 Customers
9 Global Mucin 1 Analyzing Market Dynamics
- 9.1 Mucin 1 Industry Trends
- 9.2 Mucin 1 Industry Drivers
- 9.3 Mucin 1 Industry Opportunities and Challenges
- 9.4 Mucin 1 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst